Navigation Links
Replidyne in Medical News

Replidyne Announces Restructuring of Operations

...t by approximately 80% to 5 employees in actions that are scheduled to take place during September 2008 and October 2008. As a result of these actions replidyne will suspend further development activities of REP3123, its investigational agent for the treatment of Clostridium difficile (C. difficile) bacteria a...

Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

... 1 Oral Session and 21 Poster Sessions ~ ~ replidyne Debuts New Clostridium difficile Program ~ LOUIS...pment organization," commented Kenneth J. Collins, replidyne President and CEO. "In particular, we will be pres... are essential for normal intestinal functioning. replidyne will present the following C. difficile posters on...

Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839

...ed with low systemic exposure, or drug absorption into the bloodstream, which is desirable for a topical antibiotic treatment. Based on these results, replidyne plans to initiate Phase II trials in children with impetigo, the most common bacterial skin infection, by the end of the year. "REP8839 is a p...
Replidyne in Medical Technology

Replidyne Discontinues Phase III Trial

...h acute exacerbation of chronic bronchitis (AECB). replidyne took this action to conserve its cash assets and s...hree adult community respiratory tract infections. replidyne has not initiated the other three trials, and cons...ance, further faropenem development will depend on replidyne securing a partner for the program. "In the inte...

Replidyne Provides Strategic Update

... with its strategic and operations priorities, replidyne has reduced headcount by approximately 35 perc... and commercial functions. -- Pipeline programs. replidyne will retain key research and development exper...lt of prioritizing these preclinical programs, replidyne has suspended the development of topical antibioti...

Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference

... website after the event for a period of 30 days. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discovering, developing, in-licen...-positive C. difficile bacteria and C. difficile-associated disease (CDAD). replidyne is pursuing the development of other novel anti-infective programs based on...

Replidyne's Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile

...hsner, Ph.D., Principal Scientist, Microbiology at replidyne during poster session 229 titled, "New Agents Acti...s novel treatment options. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...uction and spore-forming in C. difficile bacteria. replidyne is also pursuing the development of other novel an...

Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile

...tchley, Ph.D., Executive Director, Microbiology at replidyne during poster session 229 titled, "New Agents Acti...s novel treatment options. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...uction and spore-forming in C. difficile bacteria. replidyne is also pursuing the development of other novel an...

Replidyne Phase II Pediatric Trial Meets Primary Objective

...iatric antibiotic prescriptions for this illness. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discovering, developing, in-licen...nd infections, including methicillin resistant S. aureus (MRSA) infections. replidyne is also pursuing the development of other novel anti-infective products bas...

Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839

...ical antibiotic treatment. Based on these results, replidyne plans to initiate Phase II trials in children with...all impetigo treatments. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...methicillin-resistant S. aureus (MRSA) infections. replidyne is also pursuing the development of other novel an...
Replidyne in Biological Technology

Replidyne and Cardiovascular Systems Sign Merger Agreement

...e merger agreement under which CSI will merge with replidyne in an all-stock transaction. Under terms of the agreement, replidyne will issue new shares of its common stock to CSI s...ted to own 83 percent of the combined company, and replidyne shareholders are expected to own 17 percent of the...

Replidyne Announces Second Quarter 2008 Results From Operations

...cond quarter and six months ended June 30, 2008. replidyne reported a net loss of $18.7 million for the quart...basis, for the second quarter ended June 30, 2007. replidyne reported a net loss of $27.7 million for the six m...ves process." During the second quarter of 2008, replidyne announced that it had decided to terminate its lic...

Replidyne Terminates Faropenem Agreements

...or the faropenem program. As previously announced, replidyne had discontinued clinical development of faropenem...lication inhibition technology." At May 31, 2008 replidyne had cash and short term investments totaling $71.5 million. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...

Replidyne to Report First Quarter 2008 Earnings

...earnings. On Thursday, May 8, 2008 at 4:00 P.M. ET replidyne will host its annual shareholder meeting at Compan...tp://www.Replidyne.com . About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...fficile bacteria and C. difficile Infection (CDI). replidyne is pursuing the development of other novel anti-in...

Replidyne Announces 2007 Fourth Quarter and Full Year Results

...h quarter and full year ended December 31, 2007. replidyne reported a net loss of $16.9 million for the fourt...er 31, 2006. For the year ended December 31, 2007, replidyne reported net income of $7.7 million, or $0.29 per ...gnized as revenue in the period ended May 7, 2007. replidyne will not report any revenue under this agreement f...

Replidyne to Report 2007 Fourth Quarter and Year-End Earnings

...ourth quarter and year-end earnings. Additionally, replidyne will present at an upcoming investor conference in...ry 13, 2008 at 9:30 A.M. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...cteria and C. difficile-associated disease (CDAD). replidyne is pursuing the development of other novel anti-in...

Replidyne to Announce Third Quarter 2007 Earnings

...he company's website at http://www.Replidyne.com . About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discovering, developing, in-licen...-positive C. difficile bacteria and C. difficile-associated disease (CDAD). replidyne is pursuing the development of other novel anti-infective programs based on...
Other Tags
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... Step into a macabre world where ... of Virginia. Wicked Plants, the Museum’s latest featured exhibition, ... poisonous, carnivorous and diabolical plants inside of a dilapidated, ... the biochemical, physical and neurological processes between botanicals and ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
Other Contents